![](https://cdn.benzinga.com/files/images/story/2024/06/14/national-cancer-institute-nfvdkihxylu-unsplash.jpg?width=1200&height=800&fit=crop)
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
This week, an FDA advisory committee unanimously recommended approval of Eli Lilly's LLY Alzheimer's disease drug, donanemab. Pfizer's PFE phase III study of investigational gene therapy, fordadistrogene movaparvovec, for ambulatory boys with …